Relenza Time-To-Alleviation Endpoint Not Perfect But Suitable - FDA's Jolson

Glaxo's prospectively defined endpoint in Relenza studies may be imperfect but is appropriate, FDA Division of Anti-Viral Drug Products Director Heidi Jolson, MD, counseled the agency's Antiviral Drugs Advisory Committee Feb. 24.